Next Article in Journal
What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?—A Mini Review
Next Article in Special Issue
Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma
Previous Article in Journal
Electro-Persulfate Processes for the Treatment of Complex Wastewater Matrices: Present and Future
Previous Article in Special Issue
Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs

Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50139 Florence, Italy
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(16), 4818; https://doi.org/10.3390/molecules26164818
Submission received: 27 May 2021 / Revised: 5 August 2021 / Accepted: 7 August 2021 / Published: 9 August 2021
(This article belongs to the Special Issue Designed Multiple Ligands in Drug Design and Development)

Abstract

Diabetes mellitus (DM) represents a group of metabolic disorders that leads to acute and long-term serious complications and is considered a worldwide sanitary emergence. Type 2 diabetes (T2D) represents about 90% of all cases of diabetes, and even if several drugs are actually available for its treatment, in the long term, they show limited effectiveness. Most traditional drugs are designed to act on a specific biological target, but the complexity of the current pathologies has demonstrated that molecules hitting more than one target may be safer and more effective. The purpose of this review is to shed light on the natural compounds known as α-glucosidase and Protein Tyrosine Phosphatase 1B (PTP1B) dual-inhibitors that could be used as lead compounds to generate new multitarget antidiabetic drugs for treatment of T2D.
Keywords: PTP1B; α-glucosidase; insulin signaling; drug discovery; type 2 diabetes PTP1B; α-glucosidase; insulin signaling; drug discovery; type 2 diabetes
Graphical Abstract

Share and Cite

MDPI and ACS Style

Genovese, M.; Nesi, I.; Caselli, A.; Paoli, P. Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs. Molecules 2021, 26, 4818. https://doi.org/10.3390/molecules26164818

AMA Style

Genovese M, Nesi I, Caselli A, Paoli P. Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs. Molecules. 2021; 26(16):4818. https://doi.org/10.3390/molecules26164818

Chicago/Turabian Style

Genovese, Massimo, Ilaria Nesi, Anna Caselli, and Paolo Paoli. 2021. "Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs" Molecules 26, no. 16: 4818. https://doi.org/10.3390/molecules26164818

APA Style

Genovese, M., Nesi, I., Caselli, A., & Paoli, P. (2021). Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs. Molecules, 26(16), 4818. https://doi.org/10.3390/molecules26164818

Article Metrics

Back to TopTop